

# UC Irvine

## UC Irvine Previously Published Works

### Title

Hormone Use, Reproductive History, and Risk of Lung Cancer: The Women's Health Initiative Studies

### Permalink

<https://escholarship.org/uc/item/85g9t2gg>

### Journal

Journal of Thoracic Oncology, 10(7)

### ISSN

1556-0864

### Authors

Schwartz, Ann G  
Ray, Roberta M  
Cote, Michele L  
[et al.](#)

### Publication Date

2015-07-01

### DOI

10.1097/jto.0000000000000558

Peer reviewed



Published in final edited form as:

*J Thorac Oncol.* 2015 July ; 10(7): 1004–1013. doi:10.1097/JTO.0000000000000558.

## HORMONE USE, REPRODUCTIVE HISTORY AND RISK OF LUNG CANCER: THE WOMEN'S HEALTH INITIATIVE STUDIES

**Ann G. Schwartz, Ph.D., M.P.H.<sup>1,\*</sup>, Roberta M. Ray, M.S.<sup>2</sup>, Michele L. Cote, Ph.D.<sup>1</sup>, Judith Abrams, Ph.D.<sup>1</sup>, Robert J. Sokol, M.D.<sup>3</sup>, Susan L. Hendrix, D.O.<sup>4</sup>, Chu Chen, M.S., Ph.D.<sup>5</sup>, Rowan T. Chlebowski, M.D., Ph.D.<sup>6</sup>, F. Allan Hubbell, M.D., M.S.P.H.<sup>7</sup>, Charles Kooperberg, Ph.D.<sup>2</sup>, JoAnn E. Manson, M.D., Dr.P.H.<sup>8</sup>, Mary Jo O'Sullivan, M.D., Dr.P.H.<sup>9</sup>, Thomas Rohan, M.B.B.S., Ph.D.<sup>10</sup>, Marcia L. Stefanick, Ph.D.<sup>11</sup>, Jean Wactawski-Wende, Ph.D.<sup>12</sup>, Heather Wakelee, M.D.<sup>13</sup>, and Michael S. Simon, M.D., M.P.H.S.<sup>1</sup>**

<sup>1</sup> Karmanos Cancer Institute and Department of Oncology, Wayne State University, Detroit, Michigan

<sup>2</sup> Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle Washington

<sup>3</sup>C.S. Mott Center for Human Growth and Development and Department of Obstetrics and Gynecology, Wayne State University, Detroit, Michigan

<sup>4</sup>St. Joseph Mercy Oakland Hospital, Pontiac, Michigan

<sup>5</sup>Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington

<sup>6</sup> Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California

<sup>7</sup>Department of Medicine, University of California, Irvine, California

<sup>8</sup>Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts

<sup>9</sup> Department of Obstetrics and Gynecology, University of Miami School of Medicine, Miami, FL

<sup>10</sup>Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York

<sup>11</sup>Stanford Prevention Research Center, Stanford University School of Medicine, Stanford, California

<sup>12</sup>Department of Epidemiology and Environmental Health, University of Buffalo School of Public Health and Health Professions, Buffalo, NY

\*Send correspondence to: Ann G. Schwartz, Ph.D., M.P.H. Karmanos Cancer Institute 4100 John R. Detroit, MI 48201 Telephone: (313) 578-4201 Fax: (313) 578-4359 schwarta@karmanos.org.

Conflicts of Interest: For the remaining authors, R.T. Chlebowski has received speaker's fees and honorarium for advisory boards and consulting from Pfizer, Novo Nordisk, Amgen, Novartis and Genetech. H. Wakelee is currently receiving grant support from AstraZeneca, Novartis, BMS, Clovis, Xcovery, Celgene, Roche/Genetech, Medimmune and Pfizer and receives consulting fees from Peregrine. No other conflicts of interest are declared.

<sup>13</sup>Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford Cancer Institute, Stanford, California

## Abstract

**Introduction**—Results from the Women's Health Initiative (WHI) clinical trials (CT) demonstrated no increase in the risk of lung cancer in postmenopausal women treated with hormone therapy. We conducted a joint analysis of the WHI observational study data and CT data to further explore the association between estrogen and estrogen-related reproductive factors and lung cancer risk.

**Methods**—Reproductive history, oral contraceptive (OC) use, and postmenopausal hormone therapy (HT) was evaluated in 160,855 women with known HT exposures. Follow-up for lung cancer was through September 17, 2012; 2,467 incident lung cancer cases were ascertained, with median follow-up of 14 years.

**Results**—For all lung cancers, women with previous use of estrogen plus progestin of < 5 years (HR=0.84; 95% CI 0.71-0.99) were at reduced risk. A limited number of reproductive factors demonstrated associations with risk. There was a trend towards decreased risk with increasing age at menopause ( $p_{\text{trend}}=0.04$ ) and a trend towards increased risk with increasing number of live births ( $p_{\text{trend}}=0.03$ ). Reduced risk of non-small cell lung cancer was associated with age 20-29 at first live birth. Risk estimates varied with smoking history, years of HT use and previous bilateral oophorectomy.

**Conclusions**—Indirect measures of estrogen exposure to lung tissue, as used in this study, provide only weak evidence for an association between reproductive history or HT use and risk of lung cancer. More detailed mechanistic studies and evaluation of risk factors in conjunction with ER expression in the lung should continue as a role for estrogen can't be ruled out and may hold potential for prevention and treatment strategies.

## Keywords

Lung Cancer; Hormone Therapy; Reproductive History

## Introduction

In 2013, an estimated 110,110 women in the U.S. were diagnosed with lung cancer and 72,220 died from this disease <sup>1</sup>. There remains a gender gap in incidence rates with men having higher rates than women, but with the declining incidence among men and the leveling off of incidence among women only recently, this gender difference is narrowing. The lifetime risk of developing lung cancer is 6.9% in both men and women <sup>1</sup>.

While approximately 90% of lung cancer deaths are attributable to cigarette smoking in men, only 75-80% of lung cancer deaths in women are attributable to smoking <sup>2</sup>. There has been considerable debate about differences in lung cancer occurrence and characteristics between men and women. Women are more likely to have adenocarcinomas of the lung (45.0%) than men (37.2%) and are more likely to have tumors with *EGFR* mutations <sup>3</sup>. Women who never smoked are also more likely to develop lung cancer than men who have

never smoked<sup>4-7</sup>. However, the 5-year relative survival after a lung cancer diagnosis is better for women than for men (20.0% and 15.4%, respectively)<sup>1</sup>. Taken together, male-female differences in lung cancer risk, tumor characteristics and outcome have fueled investigations into the role of estrogens in lung cancer risk and prognosis.

Epidemiologic studies of estrogen as a risk factor for lung cancer have focused on reproductive and estrogen use history. Findings have been inconsistent, with reports of increased and decreased risk associated with post-menopausal hormone therapy (HT), oral contraceptive (OC) use, pregnancy and menstrual history<sup>8-31</sup>. The Women's Health Initiative (WHI) clinical trials data demonstrated that neither the use of estrogen plus progestin or estrogen alone was associated with lung cancer incidence<sup>18,19</sup>. Taken as a whole, inconsistent findings across studies are likely due to a number of factors including variations in HT dosing over time and potential misclassification of exposures, however, they suggest a possible role for exogenous estrogens (i.e., HT, OCs) in the development of lung cancer.

We evaluated the role of reproductive factors and hormone use in determining risk of lung cancer in women from both the Women's Health Initiative Observational Study (WHIOS) and Clinical Trials (CTs).

## Methods

### The Women's Health Initiative

The WHI enrolled a geographically and ethnically diverse cohort of 161,808 post-menopausal women age 50-79 years between October 1, 1993 and December 31, 1998 at 40 centers across the United States. All participants provided informed consent. Women were enrolled in one of four randomized CTs testing use of estrogen alone or estrogen plus progestin, calcium plus vitamin D (CaD), or low fat diet (dietary modification—DM) on several outcomes. In addition, the OS enrolled women who provided detailed lifestyle and medical history and were followed for disease outcomes. Details of recruitment<sup>32</sup> and baseline characteristics of study participants<sup>33</sup> have been published previously. Reproductive history (age at first birth, number of pregnancies, age at menarche, age at menopause, bilateral oophorectomy), use of unopposed estrogens, estrogen plus progesterone and/or oral contraceptives (never used, duration of use <5, 5-9, 10-14, 15+ years), were collected at the baseline clinic visit by self-report. Current users of hormone therapy (HT) were defined as women using HT at baseline in the OS, or women using HT at baseline in the DM or CaD trials (who were not participating in the HT trial) or women assigned to HT use in the HT CT. Past users of HT were defined as women not using HT at baseline in the OS, DM, or CaD CTs but who had used HT in the past, women receiving placebo in the HT CT but who had used HT in the past, or women randomized to HT who used HT in the past and completed a wash out period before going on trial. Never users of HT were defined as women never using HT in the OS or non-HT CTs or women on the placebo arm of the HT CT who had never used HT before trial initiation. Therefore, any of the participants, even those enrolled in the HT CT and randomized to HT, could have been defined as past users of HT.

The type of HT was classified as that reported at baseline for all women except for those on the intervention arm of the HT CT, for whom the assigned HT was used. Duration of use was calculated from start of use to before baseline or randomization. Self-report of age at enrollment, education, income, smoking status (never smoked more than 100 cigarettes, ever smoked more than 100 cigarettes), number of cigarettes smoked per day (<5, 5-14, 15-24, 25-34, 35-44, 45+), years smoked (<5, 1-9, 10-19, 20-29, 30-39, 40-49, 50+), age started smoking in 5-year intervals, age quit smoking in 5-year intervals, passive smoke exposure as a child and as an adult (home and work), alcohol intake, physical activity, diet and medical history were obtained at baseline.

Study participants were followed annually in the OS, and biannually through 2005 and annually thereafter in the CTs. At each follow-up, additional questionnaire data were obtained including self-report of cancer. Self-reports of cancer were confirmed by review of medical records and pathology reports. As of September 17, 2012, 2,467 lung cancers had been reported and centrally adjudicated. Of these, 2,220 were classified as non-small cell lung cancers (NSCLC), 236 were classified as small cell lung cancers (SCLC) and 11 had missing histology.

### Statistical Approach

The baseline subject questionnaire data, supplemented with data on lung cancer incidence, were used in the analysis. The primary objective of this study was to assess the association of reproductive history and use of oral contraceptives and hormone therapy, after adjustment for tobacco use and other known lung cancer risk factors, with risk of lung cancer among women. Two hundred fifty-seven women who reported a history of lung cancer on the baseline questionnaire were excluded. In addition, 696 women who were enrolled in the WHI studies but for whom there was no follow-up information were also excluded, leaving 160,855 women in this analysis, with 2,467 incident cases of lung cancer.

Associations between reproductive and hormonal factors and lung cancer incidence were assessed using Cox regression models to compute adjusted hazard ratios (HRs) and 95% confidence intervals (CIs). Time to incident lung cancer was computed as days from randomization in the CTs or enrollment in the OS to the first diagnosis of lung cancer during follow-up. Otherwise, follow-up was censored at the last documented follow-up contact, death, or September 17, 2012, whichever came first. Additional analyses were conducted, stratified by baseline smoking status (never, former, current) and in relation to risk by lung cancer histology (SCLC, NSCLC, and specific NSCLC subtypes). For the analyses of histology subtype, each subtype was treated as a separate outcome and lung cancer cases of a different subtype were censored at the time of diagnosis.

Each baseline hormonal or reproductive factor was modeled separately in relation to disease outcome. Tests for trend were performed by modeling the continuous form of the variable if it was originally collected; otherwise, a linear trend was evaluated by modeling the integer-scored categorical variable as a continuous variable. A set of covariates was selected, a priori, for adjustment of potential confounding, including age at enrollment/recruitment (continuous), race/ethnicity (white, black, other), education (less than high school, high school degree/GED, education after high school, college degree or higher), U.S. region

(Northeast, South, Midwest, West), pack-years of smoking (never smoked, <5, 5 to <20, 20), family history of cancer, personal history of asthma or emphysema, and body mass index (BMI) (<25, 25 to <30, 30). The baseline hazard function in the Cox model was stratified by age (5-year groups); hormone therapy trial randomization assignment or study enrollment (active conjugated equine estrogen [CEE] plus medroxyprogesterone acetate [MPA], placebo CEE and MPA, active CEE, placebo CEE, or not randomized), dietary modification trial randomization (intervention, control, or not randomized), CaD trial, or OS enrollment; hysterectomy status at baseline; and extension study participation.

Associations were evaluated in a multivariable model that included statistically significant covariates and risk factors. Several variables were not retained in the final multivariable model because their inclusion made no important changes to risk estimates or their interpretation. These included age at menarche, number of births, history of asthma, age at menopause, years since menopause, duration of past oral contraceptive use, and duration of prior unopposed estrogen use.

Statistical tests were two-sided, and p values less than 0.05 were considered statistically significant. All analyses were performed using the SAS system, version 9.3 (SAS Institute, Cary, NC, USA).

## RESULTS

Table 1 presents the baseline characteristics of the 160,855 women included in the analysis stratified by lung cancer status. In the entire cohort, 2,467 lung cancers were diagnosed during follow-up. After adjustment for multiple factors (see Methods and footnote on Table 2), the only variables in which there was a statistically significant relationship with lung cancer risk overall, and NSCLC specifically, included later age at first live birth and later age at menopause, both of which were associated with a reduced risk. Increasing time since menopause was associated with an increased risk (Table 2).

The only statistically significant findings with regard to hormone use were a reduction in risk associated with previous use of estrogen plus progestin of less than 5 years for all lung cancers (HR=0.84; 95% CI 0.72-0.98) and a similar reduction in risk associated with 5 to <10 years of any previous hormone use for NSCLC (HR=0.84; 95% CI 0.71-0.99). Little variation in risk in association with hormone use was seen for subtypes of NSCLC including adenocarcinomas, squamous cell carcinomas, large cell and associated subtypes, and other NSCLC or unspecified NSCLC (data not shown). There were no significant relationships to risk of SCLC.

Table 3 reports the relationship between reproductive factors and lung cancer risk after additional adjustment for all other reproductive and hormone use variables that were significant in any of the lung cancer analyses detailed in Table 2. The results by lung cancer histology are also presented in Table 3. This analysis showed that less than 5 years of previous use of estrogen plus progestin was associated with decreased risk of lung cancer (HR=0.84; 95% CI 0.71-0.99). A similar risk estimate was noted for NSCLC and SCLC, although these findings did not reach statistical significance. There was also a statistically

significant decrease in NSCLC incidence among women with a later age at first birth (HR=0.84; 95% CI 0.73-0.98), and for all lung cancers, a trend towards decreased risk with increasing age at menopause ( $p_{\text{trend}}=0.04$ ) and a trend towards increased risk with increasing number of live births ( $p_{\text{trend}}=0.03$ ) was observed.

Multivariable modeling was conducted for smoking status strata as described above (Table 4). Bilateral oophorectomy prior to enrollment was differentially associated with lung cancer risk; risk was increased in never smokers who had undergone bilateral oophorectomy (HR=1.47; 95% HR 1.00-2.16;  $p=0.049$ ) and decreased in current smokers who had undergone the same procedure (HR=0.68; 95% CI 0.51-0.90). The risk associated with this procedure was intermediate in former smokers (HR=0.92; 95% CI 0.76-1.1)( $p_{\text{trend}}=0.098$ ). Additionally, among current smokers only, women with 5 or more live births were at 34% increased risk and women with 10 or more years of previous use of estrogen plus progestin were at 62% increased risk, but this trend in risk associated with duration of use was not statistically significant.

## Discussion

This study found no consistent contributions to lung cancer risk for a wide range of reproductive history measures. This is an area in which the epidemiologic literature has been inconsistent. Decades ago, studies of adenocarcinoma of the lung reported that early age at menopause was associated with decreased risk<sup>8</sup>, and non-significant increases in risk were associated with later age at menarche, surgical menopause or early menopause and hormone use<sup>22</sup>. Other studies have reported no association between lung cancer risk and reproductive factors<sup>12,27</sup>, increased risk associated with increased parity<sup>28</sup>, or decreased risk with increasing age at first live birth<sup>10</sup>. In cohort studies, adenocarcinoma risk was reduced with late menarche and increased with early age at menopause (including that resulting from bilateral oophorectomy particularly prior to age 40)<sup>16</sup>, and overall lung cancer risk was increased in women having 5 or more children, a finding we replicated only among current smokers, while decreased for women giving birth for the first time after age 30<sup>31</sup>. Boggs et al. report non-significant increased risk of lung cancer in African American women with a history of bilateral oophorectomy before age 40 and fewer than 2 years of hormone use<sup>34</sup>. We found that bilateral oophorectomy was differentially associated with lung cancer risk; risk was increased in never smokers (HR=1.47; 95% HR 1.00-2.16;  $p=0.049$ ) and decreased in smokers (HR=0.68; 95% CI 0.51-0.90). These findings need further exploration to untangle contributions from the underlying reason for bilateral oophorectomy, age at surgery, hormone use before and after surgery, and timing of cigarette exposure. Overall, however, published work, like our study, does not support the idea that reproductive history independently contributes to lung cancer risk.

The epidemiologic literature is also inconsistent with regard to the role of hormone use (both HT and OCs) in lung cancer risk. The overall results presented here suggest that OC and HT use are not associated with risk of lung cancer. Only in current smokers do we find increased risk associated with 10 or more years of estrogen plus progestin use. There have been several pooled or meta-analyses of menopausal hormone therapy and risk of lung cancer that included many of the same studies<sup>14,15,21,35</sup>. Of the 11 studies and over 220,000 participants



included in the analysis by Oh et al., the pooled estimate of relative risk for lung cancer associated with HT use was 0.87 (95% CI 0.74-1.02), a non-statistically significant reduction in risk<sup>14</sup>. Among cohort studies, the estimated relative risk was 1.01 (95% CI 0.74-1.38), while among case-control studies the estimate was 0.81 (95% CI 0.68-0.97). Of the 11 studies included, one study reported increased risk<sup>8</sup>, four studies reported no association<sup>10,12,23,36</sup>, and three studies reported decreased risk<sup>11,37,38</sup> associated with HT use. Another meta-analysis of 25 studies showed an OR of 0.91 (95% CI 0.83-0.99) for the association between HT use and lung cancer risk<sup>35</sup>, while a pooled analysis of 6 case-control studies reported an OR of 0.77 (95% CI 0.66-0.90)<sup>21</sup>. Several large cohort studies, including the WHI CTs, have reported no association between HT use and incidence of lung cancer<sup>16-19</sup>. The study by Schwartz et al. is the only one to evaluate risk by ER expression in the lung tumors<sup>12</sup>. Decreased risk of estrogen receptor (ER) positive NSCLC was reported in post-menopausal women taking HT (OR=0.42; 95% CI 0.24-0.74), with no association seen for ER negative tumors<sup>12</sup>. The WHI did not include a determination of lung tumor ER receptor expression so it was not possible to evaluate differential effects of hormone use in ER positive versus ER negative lung cancer.

While not a primary analysis topic for this study, an important note is that 55% of the lung cancers were diagnosed among former smokers. We estimated, based on the data available, that 69% of these former smokers had quit smoking more than 15 years before lung cancer diagnosis. This suggests that there is a large population of longer term women former smokers at risk.

This study has several strengths including its prospective nature and large sample size. The prospective design allowed for collection of exposure data before lung cancer diagnosis. However, there were also some limitations. While the CT data provide the best opportunity for understanding the relationship between HT use and lung cancer risk, only a small number of lung cancer cases developed in the CT arms. All study arms collected smoking dose and duration as categorical variables, and therefore did not allow for specific pack-years of exposure to be calculated. This may have resulted in residual confounding within smoking category. The other limitation is not having tumor ER expression data. Estrogen exposure may differentially affect development and/or progression of tumors with specific characteristics. Hormone use data also may not accurately reflect local estrogen level in the lung and therefore null associations between hormone use and lung cancer risk should not rule out the potential for a role of estrogen in lung carcinogenesis. Multiple pathways of estrogen action exist<sup>39-48</sup> and estrogen levels in lung tissue, both from endogenous and exogenous estrogens, have never been measured, so the role of estrogen in lung cancer risk is still an open question.

In conclusion, this large, prospective study of lung cancer in women did not find strong associations with specific reproductive variables and risk, and provided only weak support for a role of hormone use in the etiology of lung cancer. There remain questions about estrogen and lung cancer risk that will not easily be answered by studies focusing on hormone use. The interplay between cigarette smoking, estrogen, genetic susceptibility and lung cancer is complex and continued study is necessary to tease apart these relationships.



## ACKNOWLEDGEMENTS

**WHI Program Office:** (National Heart, Lung, and Blood Institute, Bethesda, Maryland) Jacques Rossouw, Shari Ludlam, Dale Burwen, Joan McGowan, Leslie Ford, and Nancy Geller

**WHI Clinical Coordinating Center: Clinical Coordinating Center:** (Fred Hutchinson Cancer Research Center, Seattle, WA) Garnet Anderson, Ross Prentice, Andrea LaCroix, and Charles Kooperberg

**WHI Investigators and Academic Centers:** (Brigham and Women's Hospital, Harvard Medical School, Boston, MA) JoAnn E. Manson; (MedStar Health Research Institute/Howard University, Washington, DC) Barbara V. Howard; (Stanford Prevention Research Center, Stanford, CA) Marcia L. Stefanick; (The Ohio State University, Columbus, OH) Rebecca Jackson; (University of Arizona, Tucson/Phoenix, AZ) Cynthia A. Thomson; (University at Buffalo, Buffalo, NY) Jean Wactawski-Wende; (University of Florida, Gainesville/Jacksonville, FL) Marian Limacher; (University of Iowa, Iowa City/Davenport, IA) Robert Wallace; (University of Pittsburgh, Pittsburgh, PA) Lewis Kuller; (Wake Forest University School of Medicine, Winston-Salem, NC) Sally Shumaker

Sources of Support: The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services through contracts HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, and HHSN271201100004C. Additional support comes from NIH P30CA22453.

## REFERENCES

1. [November 13, 2013] SEER Cancer Statistics Factsheets: Lung and Bronchus Cancer. <http://seer.cancer.gov/statfacts/html/lungb.html>.
2. Hecht SS. Tobacco smoke carcinogens and lung cancer. *J Natl Cancer Inst.* Jul 21; 1999 91(14): 1194–1210. [PubMed: 10413421]
3. Tam IY, Chung LP, Suen WS, et al. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. *Clin Cancer Res.* Mar 1; 2006 12(5):1647–1653. [PubMed: 16533793]
4. Zang EA, Wynder EL. Differences in lung cancer risk between men and women: examination of the evidence. *J Natl Cancer Inst.* Feb 21; 1996 88(3-4):183–192. [PubMed: 8632492]
5. Kovalchik SA, De Matteis S, Landi MT, et al. A regression model for risk difference estimation in population-based case-control studies clarifies gender differences in lung cancer risk of smokers and never smokers. *BMC medical research methodology.* Nov 19; 2013 13(1):143. [PubMed: 24252624]
6. Thun MJ, Hannan LM, Adams-Campbell LL, et al. Lung cancer occurrence in never-smokers: an analysis of 13 cohorts and 22 cancer registry studies. *PLoS Med.* Sep 30; 2008 5(9):e185. [PubMed: 18788891]
7. Wakelee HA, Chang ET, Gomez SL, et al. Lung cancer incidence in never smokers. *J Clin Oncol.* Feb 10; 2007 25(5):472–478. [PubMed: 17290054]
8. Taioli E, Wynder EL. Re: Endocrine factors and adenocarcinoma of the lung in women. *J Natl Cancer Inst.* Jun 1; 1994 86(11):869–870. [PubMed: 8182770]
9. Liu Y, Inoue M, Sobue T, Tsugane S. Reproductive factors, hormone use and the risk of lung cancer among middle-aged never-smoking Japanese women: a large-scale population-based cohort study. *International journal of cancer.* Nov 20; 2005 117(4):662–666.
10. Kreuzer M, Gerken M, Heinrich J, Kreienbrock L, Wichmann HE. Hormonal factors and risk of lung cancer among women? *International journal of epidemiology.* Apr; 2003 32(2):263–271. [PubMed: 12714547]
11. Schabath MB, Wu X, Vassilopoulou-Sellin R, Vaporciyan AA, Spitz MR. Hormone replacement therapy and lung cancer risk: a case-control analysis. *Clin Cancer Res.* Jan 1; 2004 10(1 Pt 1):113–123. [PubMed: 14734459]
12. Schwartz AG, Wenzlaff AS, Prysak GM, et al. Reproductive factors, hormone use, estrogen receptor expression and risk of non small-cell lung cancer in women. *J Clin Oncol.* Dec 20; 2007 25(36):5785–5792. [PubMed: 18089876]

13. Chen KY, Hsiao CF, Chang GC, et al. EGFR polymorphisms, hormone replacement therapy and lung adenocarcinoma risk: analysis from a genome-wide association study in never-smoking women. *Carcinogenesis*. Mar; 2013 34(3):612–619. [PubMed: 23239743]
14. Oh SW, Myung SK, Park JY, Lym YL, Ju W. Hormone therapy and risk of lung cancer: a meta-analysis. *J Womens Health (Larchmt)*. Feb; 2010 19(2):279–288. [PubMed: 20095904]
15. Greiser CM, Greiser EM, Doren M. Menopausal hormone therapy and risk of lung cancer-Systematic review and meta-analysis. *Maturitas*. Mar; 2010 65(3):198–204. [PubMed: 20031346]
16. Brinton LA, Gierach GL, Andaya A, et al. Reproductive and hormonal factors and lung cancer risk in the NIH-AARP Diet and Health Study cohort. *Cancer Epidemiol Biomarkers Prev*. May; 2011 20(5):900–911. [PubMed: 21467241]
17. Clague J, Reynolds P, Sullivan-Halley J, et al. Menopausal hormone therapy does not influence lung cancer risk: results from the California Teachers Study. *Cancer Epidemiol Biomarkers Prev*. Mar; 2011 20(3):560–564. [PubMed: 21266521]
18. Chlebowski RT, Anderson GL, Manson JE, et al. Lung cancer among postmenopausal women treated with estrogen alone in the women's health initiative randomized trial. *J Natl Cancer Inst*. Sep 22; 2010 102(18):1413–1421. [PubMed: 20709992]
19. Chlebowski RT, Schwartz AG, Wakelee H, et al. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. *Lancet*. Oct 10; 2009 374(9697):1243–1251. [PubMed: 19767090]
20. Slatore CG, Chien JW, Au DH, Satia JA, White E. Lung cancer and hormone replacement therapy: association in the vitamins and lifestyle study. *J Clin Oncol*. Mar 20; 2010 28(9):1540–1546. [PubMed: 20159813]
21. Pesatori AC, Carugno M, Consonni D, et al. Hormone use and risk for lung cancer: a pooled analysis from the International Lung Cancer Consortium (ILCCO). *British journal of cancer*. Oct 1; 2013 109(7):1954–1964. [PubMed: 24002594]
22. Wu AH, Yu MC, Thomas DC, Pike MC, Henderson BE. Personal and family history of lung disease as risk factors for adenocarcinoma of the lung. *Cancer Res*. Dec 15; 1988 48(24 Pt 1):7279–7284. [PubMed: 3191498]
23. Elliott AM, Hannaford PC. Use of exogenous hormones by women and lung cancer: evidence from the Royal College of General Practitioners' Oral Contraception Study. *Contraception*. Apr; 2006 73(4):331–335. [PubMed: 16531161]
24. Meinhold CL, Berrington de Gonzalez A, Bowman ED, et al. Reproductive and hormonal factors and the risk of nonsmall cell lung cancer. *International journal of cancer*. Mar 15; 2011 128(6):1404–1413.
25. Zhang Y, Yin Z, Shen L, Wan Y, Zhou B. Menstrual factors, reproductive factors and lung cancer risk: a meta-analysis. *Zhongguo fei ai za zhi = Chinese journal of lung cancer*. Dec 20; 2012 15(12):701–719. [PubMed: 23249716]
26. Lim WY, Chen Y, Chuah KL, et al. Female reproductive factors, gene polymorphisms in the estrogen metabolism pathway, and risk of lung cancer in Chinese women. *Am J Epidemiol*. Mar 15; 2012 175(6):492–503. [PubMed: 22331461]
27. Dahabreh IJ, Trikalinos TA, Paulus JK. Parity and risk of lung cancer in women: systematic review and meta-analysis of epidemiological studies. *Lung Cancer*. May; 2012 76(2):150–158. [PubMed: 22169171]
28. Paulus JK, Asomaning K, Kraft P, Johnson BE, Lin X, Christiani DC. Parity and risk of lung cancer in women. *Am J Epidemiol*. Mar 1; 2010 171(5):557–563. [PubMed: 20123687]
29. Seow A, Koh WP, Wang R, Lee HP, Yu MC. Reproductive variables, soy intake, and lung cancer risk among nonsmoking women in the Singapore Chinese Health Study. *Cancer Epidemiol Biomarkers Prev*. Mar; 2009 18(3):821–827. [PubMed: 19240237]
30. Weiss JM, Lacey JV Jr, Shu XO, et al. Menstrual and reproductive factors in association with lung cancer in female lifetime nonsmokers. *Am J Epidemiol*. Dec 1; 2008 168(11):1319–1325. [PubMed: 18849300]
31. Kabat GC, Miller AB, Rohan TE. Reproductive and hormonal factors and risk of lung cancer in women: a prospective cohort study. *International journal of cancer*. May 15; 2007 120(10):2214–2220.

32. Hays J, Hunt JR, Hubbell FA, et al. The Women's Health Initiative recruitment methods and results. *Annals of epidemiology*. Oct; 2003 13(9 Suppl):S18–77. [PubMed: 14575939]
33. Langer RD, White E, Lewis CE, Kotchen JM, Hendrix SL, Trevisan M. The Women's Health Initiative Observational Study: baseline characteristics of participants and reliability of baseline measures. *Annals of epidemiology*. Oct; 2003 13(9 Suppl):S107–121. [PubMed: 14575943]
34. Boggs DA, Palmer JR, Rosenberg L. Bilateral oophorectomy and risk of cancer in African American women. *Cancer Causes Control*. Apr; 2014 25(4):507–513. [PubMed: 24487726]
35. Yao Y, Gu X, Zhu J, Yuan D, Song Y. Hormone replacement therapy in females can decrease the risk of lung cancer: a meta-analysis. *PLoS One*. 2013; 8(8):e71236. [PubMed: 23967172]
36. Blackman JA, Coogan PF, Rosenberg L, et al. Estrogen replacement therapy and risk of lung cancer. *Pharmacoepidemiology and drug safety*. Oct-Nov;2002 11(7):561–567. [PubMed: 12462132]
37. Chen KY, Hsiao CF, Chang GC, et al. Hormone replacement therapy and lung cancer risk in Chinese. *Cancer*. Oct 15; 2007 110(8):1768–1775. [PubMed: 17879370]
38. Ramnath N, Menezes RJ, Loewen G, et al. Hormone replacement therapy as a risk factor for non-small cell lung cancer: results of a case-control study. *Oncology*. 2007; 73(5-6):305–310. [PubMed: 18493157]
39. Stabile LP, Davis AL, Gubish CT, et al. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. *Cancer Res*. Apr 1; 2002 62(7):2141–2150. [PubMed: 11929836]
40. Kushner PJ, Agard DA, Greene GL, et al. Estrogen receptor pathways to AP-1. *The Journal of steroid biochemistry and molecular biology*. Nov 30; 2000 74(5):311–317. [PubMed: 11162939]
41. Umayahara Y, Kawamori R, Watada H, et al. Estrogen regulation of the insulin-like growth factor I gene transcription involves an AP-1 enhancer. *The Journal of biological chemistry*. Jun 10; 1994 269(23):16433–16442. [PubMed: 8206951]
42. Paech K, Webb P, Kuiper GG, et al. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. *Science*. Sep 5; 1997 277(5331):1508–1510. [PubMed: 9278514]
43. Hershberger PA, Vasquez AC, Kanterewicz B, Land S, Siegfried JM, Nichols M. Regulation of endogenous gene expression in human non-small cell lung cancer cells by estrogen receptor ligands. *Cancer Res*. Feb 15; 2005 65(4):1598–1605. [PubMed: 15735050]
44. Siegfried JM. Women and lung cancer: does oestrogen play a role? *The lancet oncology*. Aug; 2001 2(8):506–513. [PubMed: 11905727]
45. Atanaskova N, Keshamouni VG, Krueger JS, Schwartz JA, Miller F, Reddy KB. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance. *Oncogene*. Jun 6; 2002 21(25):4000–4008. [PubMed: 12037682]
46. Yu J, Astrinidis A, Howard S, Henske EP. Estradiol and tamoxifen stimulate LAM-associated angiomyolipoma cell growth and activate both genomic and nongenomic signaling pathways. *American journal of physiology*. Apr; 2004 286(4):L694–700. [PubMed: 12922981]
47. Stabile LP, Lyker JS, Gubish CT, Zhang W, Grandis JR, Siegfried JM. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. *Cancer Res*. Feb 15; 2005 65(4):1459–1470. [PubMed: 15735034]
48. Spivack SD, Hurteau GJ, Fasco MJ, Kaminsky LS. Phase I and II carcinogen metabolism gene expression in human lung tissue and tumors. *Clin Cancer Res*. Dec 1; 2003 9(16 Pt 1):6002–6011. [PubMed: 14676126]

**Table 1**

Baseline characteristics of WHI participants by lung cancer status.

		Non-cases (N=158388)		Lung cancer cases (N=2467)		P-Value
		n	%	n	%	
<i>Age group at screening (5 yr intervals)</i>	<i>50-54</i>	21258	13.4	161	6.5	<.001
	<i>55-59</i>	31470	19.9	330	13.4	.
	<i>60-64</i>	36432	23.0	567	23.0	.
	<i>65-69</i>	34456	21.8	745	30.2	.
	<i>70-74</i>	24284	15.3	485	19.7	.
	<i>75-79</i>	10488	6.6	179	7.3	.
<i>Race/ethnicity</i>	<i>White</i>	130738	82.5	2198	89.1	<.001
	<i>Black</i>	14328	9.0	152	6.2	.
	<i>Hispanic</i>	6306	4.0	35	1.4	.
	<i>American Indian</i>	692	0.4	10	0.4	.
	<i>Asian/Pacific Islander</i>	4119	2.6	38	1.5	.
	<i>Unknown</i>	2205	1.4	34	1.4	.
<i>Education</i>	<i>Less than high school</i>	8362	5.3	137	5.6	<.001
	<i>High school diploma/GED</i>	27003	17.0	457	18.5	.
	<i>School after high school</i>	59552	37.6	1017	41.2	.
	<i>College degree or higher</i>	62280	39.3	841	34.1	.
	<i>Missing</i>	1191	0.8	15	0.6	.
<i>U. S. region</i>	<i>Northeast</i>	36109	22.8	658	26.7	<.001
	<i>South</i>	41024	25.9	582	23.6	.
	<i>Midwest</i>	34863	22.0	492	19.9	.
	<i>West</i>	46392	29.3	735	29.8	.
<i>Smoking status</i>	<i>Never</i>	80649	50.9	382	15.5	<.001
	<i>Past</i>	65320	41.2	1359	55.1	.
	<i>Current</i>	10363	6.5	691	28.0	.
	<i>Missing</i>	2056	1.3	35	1.4	.
<i>Pack years of smoking (categorical)</i>	<i>Never-smoker</i>	80649	50.9	382	15.5	<.001
	<i>&lt;5</i>	22374	14.1	133	5.4	.
	<i>5 - &lt;20</i>	21940	13.9	346	14.0	.
	<i>&gt;=20</i>	27791	17.5	1506	61.0	.
	<i>Missing</i>	5634	3.6	100	4.1	.
<i>History of emphysema</i>	<i>No</i>	143852	90.8	2090	84.7	<.001
	<i>Yes</i>	5363	3.4	220	8.9	.
	<i>Missing</i>	9173	5.8	157	6.4	.
<i>History of asthma</i>	<i>No</i>	144044	90.9	2193	88.9	<.001
	<i>Yes</i>	12224	7.7	245	9.9	.
	<i>Missing</i>	2120	1.3	29	1.2	.
<i>Age at menarche</i>	<i>&lt;12</i>	34607	21.8	552	22.4	0.686
	<i>12</i>	41186	26.0	632	25.6	.

		Non-cases (N=158388)		Lung cancer cases (N=2467)		P-Value
		n	%	n	%	
Number of pregnancies	13	45625	28.8	685	27.8	.
	>13	36342	22.9	587	23.8	.
	Missing	628	0.4	11	0.4	.
	None	14596	9.2	211	8.6	0.002
	1	11069	7.0	162	6.6	.
	2	30475	19.2	438	17.8	.
	3	35280	22.3	517	21.0	.
	4	27310	17.2	435	17.6	.
	>=5	38895	24.6	695	28.2	.
Number of live births	Missing	763	0.5	9	0.4	.
	None	18803	11.9	286	11.6	0.103
	>=5	23204	14.7	396	16.1	.
	1 - 2	53367	33.7	777	31.5	.
	3 - 4	62062	39.2	994	40.3	.
Age at first birth, y (categories)	Missing	952	0.6	14	0.6	.
	Never preg/No term preg	18803	11.9	286	11.6	0.003
	<20	20065	12.7	379	15.4	.
	20 - 29	92716	58.5	1408	57.1	.
	30+	11728	7.4	173	7.0	.
	Missing	15076	9.5	221	9.0	.
Age at menopause	< 40	14193	9.0	290	11.8	<.001
	40 - 50	51635	32.6	918	37.2	.
	50+	76655	48.4	1020	41.3	.
	Missing	15905	10.0	239	9.7	.
Years since menopause	< 5 yrs	20239	12.8	151	6.1	<.001
	5-9 yrs	26996	17.0	278	11.3	.
	10-14 yrs	29424	18.6	441	17.9	.
	15-19 yrs	25464	16.1	441	17.9	.
	>= 20 yrs	47031	29.7	1007	40.8	.
	Missing	9234	5.8	149	6.0	.
Oral contraceptive use ever	No	92686	58.5	1521	61.7	0.007
	Yes	65699	41.5	946	38.3	.
	Missing	3	0.0	0	0.0	.
Duration of OC use	Non-User	92732	58.5	1524	61.8	0.023
	< 5 Years	36324	22.9	512	20.8	.
	5 - < 10 Years	14922	9.4	212	8.6	.
	10+ Years	14407	9.1	219	8.9	.
	Missing	3	0.0	0	0.0	.
Unopposed estrogen use ever	No	101910	64.3	1555	63.0	0.393
	Yes	56475	35.7	912	37.0	.

		Non-cases (N=158388)		Lung cancer cases (N=2467)		P-Value
		n	%	n	%	
	<i>Missing</i>	3	0.0	0	0.0	.
<i>Duration of previous unopposed estrogen use</i>	<i>Non-User</i>	101910	64.3	1555	63.0	0.055
	<i>&lt; 5 Years</i>	20931	13.2	361	14.6	.
	<i>5 - &lt; 10 Years</i>	11168	7.1	149	6.0	.
	<i>10+ Years</i>	24374	15.4	402	16.3	.
	<i>Missing</i>	5	0.0	0	0.0	.
<i>Estrogen + progesterone use ever</i>	<i>No</i>	116991	73.9	1937	78.5	<.001
	<i>Yes</i>	41394	26.1	530	21.5	.
	<i>Missing</i>	3	0.0	0	0.0	.
<i>Duration of previous estrogen + progestin use</i>	<i>Non-User</i>	116991	73.9	1937	78.5	<.001
	<i>&lt; 5 Years</i>	20921	13.2	237	9.6	.
	<i>5 - &lt; 10 Years</i>	11239	7.1	129	5.2	.
	<i>10+ Years</i>	9232	5.8	164	6.6	.
	<i>Missing</i>	5	0.0	0	0.0	.
<i>Body-mass index (kg/m2), baseline</i>	<i>&lt;25</i>	55070	34.8	974	39.5	<.001
	<i>25 - &lt;30</i>	54547	34.4	836	33.9	.
	<i>&gt;=30</i>	47386	29.9	632	25.6	.
	<i>Missing</i>	1385	0.9	25	1.0	.
<i>Family history of cancer</i>	<i>No</i>	50859	32.1	671	27.2	<.001
	<i>Yes</i>	100480	63.4	1678	68.0	.
	<i>Missing</i>	7049	4.5	118	4.8	.

**Table 2**  
Risk of developing lung cancer in relationship to baseline reproductive and hormonal factors in WHI participants.

	All lung cancer (N=2467)						NSCLC (N=2220)						SCLC (N=236)								
	Cases	HR	LCI	UCI	P-Value	Cases	HR	LCI	UCI	P-Value	Cases	HR	LCI	UCI	P-Value	Cases	HR	LCI	UCI	P-Value	
<i>Age at menarche</i>																					
<12	478	1.00	.	.	0.334	431	1.00	.	.	0.290	46	1.00	.	.	0.931						
12	518	0.91	(0.80-	1.03)	.	466	0.90	(0.79-	1.03)	.	49	0.94	(0.62-	1.41)	.						
13	590	0.92	(0.82-	1.04)	.	532	0.92	(0.81-	1.04)	.	57	0.98	(0.66-	1.45)	.						
>13	501	0.96	(0.85-	1.09)	.	447	0.95	(0.83-	1.09)	.	50	1.03	(0.69-	1.54)	.						
<i>Parity</i>																					
Parous	1841	1.00	.	.	0.674	1647	1.00	.	.	0.958	185	1.00	.	.	0.202						
<i>Nulliparous</i>																					
1 - 2	240	0.97	(0.85-	1.11)	.	224	1.00	(0.87-	1.16)	.	16	0.71	(0.43-	1.20)	.						
3 - 4	659	1.00	.	.	0.052	596	1.00	.	.	0.130	60	1.00	.	.	0.157						
>=5	842	1.06	(0.96-	1.18)	.	755	1.06	(0.95-	1.18)	.	83	1.09	(0.78-	1.53)	.						
<20	340	1.14	(1.00-	1.31)	.	296	1.11	(0.96-	1.29)	.	42	1.36	(0.91-	2.03)	.						
<20	317	1.00	.	.	0.064	289	1.00	.	.	0.030	27	1.00	.	.	0.524						
20 - 29	1212	0.87	(0.76-	0.99)	.	1071	0.81	(0.70-	0.93)	.	136	1.55	(1.00-	2.42)	.						
30+	141	0.85	(0.69-	1.05)	.	133	0.83	(0.67-	1.03)	.	8	0.87	(0.39-	1.98)	.						
<40	253	1.00	.	.	<0.001	224	1.00	.	.	<0.001	28	1.00	.	.	0.482						
40 - 50	795	0.90	(0.77-	1.04)	.	706	0.89	(0.76-	1.04)	.	84	0.93	(0.59-	1.45)	.						
50+	875	0.73	(0.62-	0.85)	.	795	0.73	(0.62-	0.86)	.	77	0.68	(0.42-	1.10)	.						
<5 yrs	128	1.00	.	.	<0.001	120	1.00	.	.	<0.001	8	1.00	.	.	0.256						
5-9 yrs	245	1.05	(0.83-	1.32)	.	219	1.01	(0.79-	1.28)	.	25	1.59	(0.68-	3.70)	.						
10-14 yrs	374	1.17	(0.92-	1.49)	.	334	1.14	(0.89-	1.47)	.	40	1.62	(0.68-	3.87)	.						
15-19 yrs	378	1.24	(0.97-	1.60)	.	343	1.25	(0.96-	1.62)	.	32	1.29	(0.52-	3.22)	.						
>= 20 yrs	882	1.54	(1.20-	1.98)	.	785	1.52	(1.17-	1.97)	.	92	1.90	(0.77-	4.68)	.						
<i>Bilateral oophorectomy</i>																					
No	1636	1.00	.	.	0.185	1474	1.00	.	.	0.229	159	1.00	.	.	0.281						
Yes	409	0.91	(0.80-	1.04)	.	369	0.92	(0.80-	1.06)	.	36	0.79	(0.51-	1.22)	.						
<i>Duration of OC use</i>																					
Non-User	1297	1.00	.	.	0.934	1170	1.00	.	.	0.908	122	1.00	.	.	0.407						
<5 Years	433	0.98	(0.87-	1.10)	.	386	0.96	(0.85-	1.09)	.	43	1.06	(0.74-	1.52)	.						
5 - <10 Years	183	1.05	(0.89-	1.23)	.	165	1.04	(0.87-	1.23)	.	18	1.23	(0.74-	2.07)	.						
10+ Years	178	0.98	(0.84-	1.16)	.	159	0.96	(0.81-	1.14)	.	19	1.25	(0.76-	2.07)	.						
Non-User	969	1.00	.	.	0.503	864	1.00	.	.	0.589	100	1.00	.	.	0.663						



	All lung cancer (N=2467)					NSCLC (N=2220)					SCLC (N=236)				
	Cases	HR	LCI	UCI	P-Value	Cases	HR	LCI	UCI	P-Value	Cases	HR	LCI	UCI	P-Value
< 5 Years	421	1.00	(0.89- 1.12)			378	0.99	(0.88- 1.12)			43	1.09	(0.76- 1.58)		
5 - < 10 Years	212	0.86	(0.74- 1.01)			188	0.84	(0.71- 0.99)			23	1.12	(0.69- 1.80)		
10+ Years	489	0.93	(0.82- 1.05)			450	0.95	(0.83- 1.08)			36	0.76	(0.49- 1.17)		
Duration of previous unopposed estrogen use	1311	1.00			0.634	1178	1.00				127	1.00			0.510
< 5 Years	306	1.08	(0.94- 1.23)			270	1.06	(0.92- 1.23)			36	1.27	(0.85- 1.89)		
5 - < 10 Years	127	0.88	(0.72- 1.07)			112	0.86	(0.70- 1.06)			14	1.05	(0.58- 1.91)		
10+ Years	347	0.94	(0.82- 1.09)			320	0.97	(0.83- 1.13)			25	0.72	(0.43- 1.20)		
Duration of previous estrogen + progestin use	1643	1.00			0.728	1470	1.00				165	1.00			0.809
< 5 Years	199	0.84	(0.72- 0.98)			184	0.85	(0.72- 1.00)			15	0.76	(0.44- 1.32)		
5 - < 10 Years	112	0.84	(0.69- 1.03)			100	0.81	(0.66- 1.01)			12	1.22	(0.66- 2.26)		
10+ Years	137	1.01	(0.85- 1.22)			126	1.02	(0.84- 1.23)			10	0.93	(0.48- 1.80)		
Use of postmenopausal hormone therapy	812	1.00			0.142	731	1.00				76	1.00			0.963
Past users only	350	1.02	(0.90- 1.16)			313	1.01	(0.89- 1.16)			37	1.16	(0.77- 1.75)		
Current users	928	0.91	(0.81- 1.03)			835	0.91	(0.80- 1.02)			89	0.97	(0.66- 1.45)		

Numbers in the body of the table are for women with no missing values for the covariate of interest and the adjustment variables.

Histology information was missing for 11 patients.

NSCLC = non-small cell lung cancer; SCLC = small cell lung cancer; HR=hazard ratio; LCI=95% confidence interval lower limit; UCI=95% confidence interval upper limit.

Risk estimates were adjusted for age at screening (continuous), race/ethnicity, pack-years of smoking (categories), education, US region, history of emphysema, history of asthma, BMI, and family history of cancer; models were stratified by 5-year age group, baseline hysterectomy status, study type (OS or trial arm for clinical trial participants), and WHI extension study participation.

P-value is for trend if > 2 categories. Trend tests were based on the continuous form of the variable if originally collected as such.

\* Among parous women only

\*\* Includes hormone trial participants who had been non-users or past users but were randomized to active E-alone or active E+P 7

Table 3

Multivariable model for lung cancer risk in WHI participants.

	Lung cancer (N=1713)					NSCLC (N=1541)					SCLC (N=167)				
	HR	LCI	UCI	P-value	*	HR	LCI	UCI	P-value	*	HR	LCI	UCI	P-value	*
<i>Parity</i>															
<i>Nulliparous</i>	0.95	(0.77-	1.16)	0.589		0.92	(0.75-	1.14)	0.465		1.10	(0.53-	2.28)	0.804	
<i>Number of live births</i>															
<i>1 - 2</i>	1.00	Reference		0.030		1.00	Reference		0.094		1.00	Reference		0.091	
<i>3 - 4</i>	1.10	(0.98-	1.24)			1.08	(0.96-	1.23)			1.25	(0.85-	1.82)		
<i>&gt;=5</i>	1.17	(1.00-	1.36)			1.13	(0.96-	1.33)			1.52	(0.95-	2.41)		
<i>Age at first birth</i>															
<i>&lt;20</i>	1.00	Reference		0.426		1.00	Reference		0.287		1.00	Reference		0.521	
<i>20 - 29</i>	0.89	(0.77-	1.03)			0.84	(0.73-	0.98)			1.40	(0.88-	2.23)		
<i>30+</i>	0.96	(0.77-	1.20)			0.94	(0.75-	1.19)			0.97	(0.42-	2.26)		
<i>Age at menopause</i>															
<i>&lt;40</i>	1.00	Reference		0.042		1.00	Reference		0.058		1.00	Reference		0.435	
<i>40 - 50</i>	0.91	(0.77-	1.08)			0.91	(0.76-	1.08)			0.95	(0.57-	1.61)		
<i>50+</i>	0.80	(0.64-	1.00)			0.80	(0.63-	1.02)			0.76	(0.37-	1.58)		
<i>Years since menopause</i>															
<i>&lt;5 yrs</i>	1.00	Reference		0.275		1.00	Reference		0.311		1.00	Reference		0.705	
<i>5-9 yrs</i>	0.99	(0.76-	1.27)			0.97	(0.74-	1.27)			1.23	(0.48-	3.15)		
<i>10-14 yrs</i>	1.06	(0.80-	1.39)			1.03	(0.78-	1.38)			1.44	(0.53-	3.87)		
<i>15-19 yrs</i>	1.03	(0.76-	1.40)			1.04	(0.76-	1.43)			1.02	(0.34-	3.09)		
<i>&gt;=20 yrs</i>	1.19	(0.83-	1.69)			1.16	(0.80-	1.68)			1.54	(0.45-	5.28)		
<i>Bilateral oophorectomy</i>															
<i>Yes</i>	0.90	(0.77-	1.04)	0.147		0.91	(0.78-	1.06)	0.211		0.73	(0.45-	1.19)	0.210	
<i>Duration of previous estrogen + progestin use</i>															
<i>Non-user</i>	1.00	Reference		0.174		1.00	Reference		0.146		1.00	Reference		0.713	
<i>&lt; 5 Years</i>	0.84	(0.71-	0.99)			0.85	(0.71-	1.02)			0.73	(0.40-	1.36)		
<i>5 - &lt; 10 Years</i>	0.89	(0.71-	1.10)			0.85	(0.68-	1.08)			1.40	(0.72-	2.71)		
<i>10+ Years</i>	0.93	(0.76-	1.14)			0.92	(0.75-	1.14)			1.07	(0.54-	2.10)		

Full model includes parity, number of live births, age at first live birth, age at menopause, years since menopause, bilateral oophorectomy, and duration of previous estrogen + progestin use. Risk estimates were further adjusted for age at screening (continuous), race/ethnicity, pack-years of smoking (categories), education, US region, history of emphysema, history of asthma, BMI, and family history of cancer; stratified by age group, baseline hysterectomy status, trial, and WHI extension study participation. Women missing any of these data were excluded from the model.

\* P-value is for trend if > 2 categories. Trend tests were based on the continuous form of the variable if originally collected. Trends for Number of live births and Age at first birth are among parous women only.

Table 4

Multivariable model for lung cancer risk in WHI participants, by smoking status at baseline.

	Never smokers (58171 women, 273 cases)				Past smokers (46795 women, 955 cases)				Current smokers (7684 women, 485 cases)			
	HR	LCI	UCI	P-value*	HR	LCI	UCI	P-value*	HR	LCI	UCI	P-value*
<i>Parity</i>												
<i>Number of live births</i>												
Nulliparous	1.13	(0.67-	1.90)	0.650	0.83	(0.63-	1.10)	0.204	1.09	(0.75-	1.60)	0.652
1 - 2	1.00	Reference		0.209	1.00	Reference		0.603	1.00	Reference		0.049
3 - 4	1.13	(0.83-	1.53)		1.08	(0.93-	1.26)		1.10	(0.88-	1.39)	
>=5	1.26	(0.85-	1.88)		1.03	(0.84-	1.27)		1.34	(1.01-	1.78)	
<i>Age at first birth</i>												
<20	1.00	Reference		0.218	1.00	Reference		0.705	1.00	Reference		0.784
20 - 29	0.72	(0.48-	1.07)		0.94	(0.77-	1.14)		0.99	(0.77-	1.27)	
30+	0.76	(0.43-	1.34)		0.97	(0.72-	1.31)		1.10	(0.71-	1.70)	
<i>Age at menopause</i>												
<40	1.00	Reference		0.735	1.00	Reference		0.088	1.00	Reference		0.345
40 - 50	1.43	(0.85-	2.41)		0.84	(0.67-	1.05)		0.95	(0.70-	1.30)	
50+	1.11	(0.59-	2.10)		0.76	(0.57-	1.03)		0.82	(0.52-	1.28)	
<i>Years since menopause</i>												
<5 yrs	1.00	Reference		0.275	1.00	Reference		0.311	1.00	Reference		0.705
5-9 yrs	1.03	(0.57-	1.86)		0.96	(0.66-	1.39)		0.87	(0.55-	1.39)	
10-14 yrs	0.89	(0.46-	1.73)		1.06	(0.72-	1.56)		0.90	(0.55-	1.48)	
15-19 yrs	0.82	(0.39-	1.74)		1.03	(0.67-	1.57)		0.87	(0.49-	1.53)	
>= 20 yrs	0.86	(0.36-	2.06)		1.07	(0.66-	1.74)		1.23	(0.63-	2.38)	
<i>Bilateral oophorectomy</i>												
Yes	1.47	(1.00-	2.16)	0.049	0.92	(0.76-	1.12)	0.425	0.68	(0.51-	0.90)	0.008
<i>Duration of previous estrogen + progestin use</i>												
Non-user	1.00	Reference		0.445	1.00	Reference		0.098	1.00	Reference		0.159
< 5 Years	0.93	(0.62-	1.40)		0.86	(0.69-	1.08)		0.86	(0.61-	1.21)	
5 - < 10 Years	0.97	(0.57-	1.63)		0.96	(0.73-	1.27)		0.87	(0.53-	1.46)	
10+ Years	1.31	(0.82-	2.10)		0.79	(0.60-	1.04)		1.62	(1.09-	2.41)	

Full model includes parity, number of live births, age at first live birth, age at menopause, years since menopause, bilateral oophorectomy, and duration of previous estrogen + progestin use. Risk estimates were further adjusted for age at screening (continuous), race/ethnicity, pack-years of smoking (categories), education, US region, history of emphysema, history of asthma, BMI, and family history of cancer; stratified by age group, baseline hysterectomy status, trial, and WHI extension study participation. Women missing any of these data were excluded from the model.

\* P-value is for trend if > 2 categories. Trend tests were based on the continuous form of the variable if originally collected. Trends for Number of live births and Age at first birth are among parous women only.